Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients

Soyyiğit, Şadan; Güloğlu, Deniz; İkincioğulları, Aydan; Seçil, Derya; Öztuna, Derya; Mungan, Dilşad; Mısırlıgil, Zeynep; Sin, Betül Ayşe

doi:10.1016/j.anai.2016.01.002

Cited by 17 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies also support that single allergen DP-SCIT give similar improvement in clinical response on both mono-sensitized and poly-sensitized patients [36, 37]. …”

Section: Discussionmentioning

confidence: 56%

Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens

Shi

Zheng²,

Chen

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Dermatophagoides pteronyssinus (DP) and Blomia tropicalis (BT) are the dominant house dust mites inducing allergic diseases in tropical climates. It is not known whether the efficacy of DP subcutaneous immunotherapy (SCIT) is similar in patients sensitized to DP alone or to both DP and BT. Method: Ninety-five children (5–17 years old) affected by asthma with rhinitis and sensitized to both DP and BT received 3 years of DP-SCIT. Clinical symptom and medication scores, serum-specific IgE and IgG₄ were evaluated during DP-SCIT. Patients were grouped based on DP and BT co-sensitization or cross-reactivity, according to positive or negative IgE to BT major allergen (BTMA). Results: After 3 years of DP-SCIT, all patients had significant reductions in symptoms and medication use. In all, 65% of the patients were free of asthma symptoms and medication use; in addition, 3% was free of rhinitis symptoms. FEV₁ in all patients were greater than 95% of predicted. DP-SCIT induced significant increases in DP- and BT-specific IgG₄. In 50% of patients, DP-specific IgG₄ increased more than 67-fold. BT-specific IgG₄ increased more than 2.5 fold. A moderate correlation (r = 0.48–0.61, p < 0.01) was found between specific IgE against DP and BT in the BTMA– group (n = 34) before and after DP-SCIT, whereas no correlation was found in the BTMA+ group (n = 61). The 2 BTMA groups responded similarly with regard to clinical improvement and increase in specific IgG₄ to both DP and BT. No safety finding of concern were reported in either group. Conclusion: DP-SCIT may be of clinical benefit to patients with IgE sensitizations to both DP and BT. DP-SCIT induces IgG₄ that cross-react with BT allergens.

show abstract

“…Other studies also support that single allergen DP-SCIT give similar improvement in clinical response on both mono-sensitized and poly-sensitized patients [36, 37]. …”

Section: Discussionmentioning

confidence: 56%

Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens

Shi

Zheng²,

Chen

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The appropriate use of immunotherapy for polysensitised allergic rhinitis patients remains unclear 12 13 Regarding house dust mite subcutaneous immunotherapy for polysensitised allergic rhinitis, Soyyigit et al 14 . and Kim et al 15 .…”

Section: Discussionmentioning

confidence: 99%

Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, it has been reported that immunotherapy with a single allergen is more effective than that with multiple allergens with regard to immunological changes, including decrease in skin reactivity level [161718]. However, as there are some reports of the clinical efficacy of multiple-allergen immunotherapy, further research will have to be conducted [15161736]. …”

Section: Discussionmentioning

confidence: 99%

“…The conventional application method for allergen administration is subcutaneous injection, but the efficacy of sublingual administration has recently been widely acknowledged [111213]. The type or number of injected antigens may differ according to the degree of sensitization of immunotherapy patients to antigens, leading to variations in the immunoclinical responses of patients [1415161718]. …”

Section: Introductionmentioning

confidence: 99%

Changes in skin reactivity and associated factors in patients sensitized to house dust mites after 1 year of allergen-specific immunotherapy

Son

Jung

Koh

et al. 2017

Asia Pacific Allergy

View full text Add to dashboard Cite

BackgroundAllergen-specific immunotherapy (SIT) can significantly improve symptoms and reduce the need for symptomatic medication.ObjectiveThe aim of this study was to investigate changes in skin reactivity to house dust mites (HDMs) as an immunologic response and associated factors after 1 year of immunotherapy.MethodsA total of 80 patients with allergic airway diseases who received subcutaneous SIT with HDMs from 2009 to 2014 were evaluated. The investigated parameters were basic demographic characteristics, skin reactivity and specific IgE for HDM, serum total IgE level, blood eosinophil counts, and medication score.ResultsThe mean levels of skin reactivity to HDMs, blood eosinophil counts, and medication scores after 1 year were significantly reduced from baseline. In univariate comparison of the changes in skin reactivity to HDMs, age ≤30 years, HDMs only as target of immunotherapy, and high initial skin reactivity (≥2) to HDMs were significantly associated with the reduction in skin test reactivity. In multivariate analysis, high initial skin reactivity and HDMs only as target allergens were significantly associated with changes in skin reactivity to HDMs. In the receiver operating characteristic curve of the initial mean skin reactivity to HDMs for more than 50% reduction, the optimal cutoff value was 2.14.ConclusionThis study showed significant reductions in allergen skin reactivity to HDMs after 1 year of immunotherapy in patients sensitized to HDMs. The extent of initial allergen skin reactivity and only HDMs as target allergen were important predictive factors for changes in skin reactivity.

show abstract

Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients

Cited by 17 publications

References 37 publications

Clinical Response to Subcutaneous <b><i>Dermatophagoides pteronyssinus</i></b> Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to <b><i>Blomia tropicalis</i></b> Allergens

Clinical Response to Subcutaneous <b><i>Dermatophagoides pteronyssinus</i></b> Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to <b><i>Blomia tropicalis</i></b> Allergens

Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites

Changes in skin reactivity and associated factors in patients sensitized to house dust mites after 1 year of allergen-specific immunotherapy

Contact Info

Product

Resources

About